Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2020 10:05 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells Deepening of Response Observed with FT596 Retreatment Duration of Response...
December 04, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response No Observed Events of Any Grade of Cytokine Release...
November 30, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
November 12, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
November 05, 2020 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress

First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma FT596 Phase 1 Study Expanded to Include Chronic Lymphocytic Leukemia First...
November 05, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting

Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event on Friday, December 4 SAN DIEGO, Nov. 05, 2020 ...
November 02, 2020 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results

SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
October 15, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
September 30, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
September 04, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces September Investor Events

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...